This is a real Lifetime opportunity folks ..THANK ME LATER !!!
Thermodox (Liver Cancer) Phase III results before year end .Thermodox has BLOCKBUSTER POTENTIAL (1-2 Billion Dollar Sales Potential )
Market cap of $146 Mil is significantly undervalued for a BIG BLOCKBUSTER = Positive results will push this low float monster into DOUBLE DIGITS like PCYC OR MDVN .
MY Tgt is minimum $20++ after Positive Results which is highly likely .
Market : $146 Mil
Cash : $24 Mil
Price : $4.40
Shares Out : 33 M
Brean Murray Carret & Co. Starts Celsion Corp (CLSN) at Buy; Expecting Positive Phase 3 Data This Year
Brean Murray Carret & Co. initiates coverage on Celsion Corp (NASDAQ: CLSN) with a Buy. .
Brean analyst says, "We believe ThermoDox will be broadly adopted once it is approved. Due to the potential ability of ThermoDox to reduce the recurrence rate in intermediate HCC patients, we are optimistic about its adoption as the future standard of care, especially given how seamlessly ThermoDox can be integrated with RFA. Its effectiveness should increase the number of RFA procedures and enable the RFA/ThermoDox combination to take market share from procedures like TACE with chemotherapy.